

Adaptimmune Therapeutics PLC  
Form SC 13G/A  
February 14, 2019

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934  
(Amendment No. 2)**

**Adaptimmune Therapeutics plc**

(Name of Issuer)

**Ordinary Shares**

(Title of Class of Securities)

**00653A107**

(CUSIP Number)

**David S. Bakst, Esq.**

**Mayer Brown LLP**

**1221 Avenue of the Americas**

**New York, New York 10020**

**(212) 506-2551**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**January 31, 2019**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

Edgar Filing: Adaptimmune Therapeutics PLC - Form SC 13G/A

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

Edgar Filing: Adaptimmune Therapeutics PLC - Form SC 13G/A

CUSIP No. 00653A107

1. Name of Reporting Person:  
Nicholas John Cross
2. Check the Appropriate Box if a Member of a Group:  
(a)    
(b)
3. SEC Use Only:
4. Citizenship or Place of Organization:  
United Kingdom
- |   |    |                                       |
|---|----|---------------------------------------|
| Number of<br>Shares<br>Beneficially<br>by Owned by<br>Each<br>Reporting<br>Person With: | 5. | Sole Voting Power:<br>29,042,800      |
|   | 6. | Shared Voting Power:<br>0             |
|   | 7. | Sole Dispositive Power:<br>29,042,800 |
|   | 8. | Shared Dispositive Power:<br>0        |
9. Aggregate Amount Beneficially Owned by Each Reporting Person:  
29,042,800 Ordinary Shares
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares:
11. Percent of Class Represented by Amount in Row (9):  
4.62%\*
12. Type of Reporting Person:  
IN

---

\* The percent of the class reported is based on 628,141,612 of the Issuer's ordinary shares outstanding as of January 31, 2019.

SCHEDULE 13G

- Item 1(a).** Name of Issuer:  
Adaptimmune Therapeutics plc
- Item 1(b).** Address of Issuer's Principal Executive Offices:  
60 Jubilee Avenue, Milton Park  
  
Abingdon, Oxfordshire OX14 4RX  
  
United Kingdom
- Item 2(a).** Name of Person Filing:  
Nicholas John Cross
- Item 2(b).** Address of Principal Business Office or, if none, Residence:  
Lashford House, Church Lane  
  
Dry Sandford  
  
Abingdon, Oxon OX13 6JP  
  
United Kingdom
- Item 2(c).** Citizenship:  
United Kingdom
- Item 2(d).** Title of Class of Securities:  
Ordinary shares, par value £0.001 per share. Certain ordinary shares are represented by American Depositary Shares (ADSs) with each ADS representing six ordinary shares.
- Item 2(e).** CUSIP Number:  
00653A107
- Item 3.** **If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**
- |     |                       |   |
|-----|-----------------------|---|
| (a) | <input type="radio"/> | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);  |
| (b) | <input type="radio"/> | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);  |
| (c) | <input type="radio"/> | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);  |
| (d) | <input type="radio"/> | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);  |
| (e) | <input type="radio"/> | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);   |
| (f) | <input type="radio"/> | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);  |
| (g) | <input type="radio"/> | A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);  |
| (h) | <input type="radio"/> | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);  |
| (i) | <input type="radio"/> | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); and |
| (j) | <input type="radio"/> | Group, in accordance with § 240.13d-1(b)(1)(ii)(J).   |

- Item 4. Ownership.**  
The information requested hereinafter is set forth in items 5 through 9 and 11 of the cover pages to this Schedule 13G. Ownership is stated as of January 31, 2019. The ownership percentage is based on 628,141,612 ordinary shares outstanding as of January 31, 2019.
- Item 5. Ownership of Five Percent or Less of a Class.**  
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.
- Item 6. Ownership of More than Five Percent on Behalf of Another Person.**  
All securities reported in this schedule are owned by the Reporting Person.
- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**  
Not applicable.
- Item 8. Identification and Classification of Members of the Group.**  
Not applicable.
- Item 9. Notice of Dissolution of Group.**  
Not applicable.
-

**Item 10. Certifications.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated February 14, 2019

**NICHOLAS JOHN CROSS**

By: /s/ Nicholas John Cross  
Name: Nicholas John Cross